Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Harrow Inc (NQ: HROW ) 47.55 -3.05 (-6.03%) Streaming Delayed Price Updated: 12:18 PM EDT, Oct 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Harrow Inc < Previous 1 2 3 4 Next > Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery October 10, 2024 From Harrow, Inc. Via Business Wire Harrow Relaunches TRIESENCE® October 03, 2024 From Harrow, Inc. Via Business Wire Harrow Announces Nashville Expansion September 25, 2024 From Harrow, Inc. Via Business Wire Harrow to Present at Three Investor Conferences in September in New York September 03, 2024 From Harrow, Inc. Via Business Wire Harrow Announces Second Quarter 2024 Financial Results August 07, 2024 From Harrow, Inc. Via Business Wire Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024 July 25, 2024 From Harrow, Inc. Via Business Wire Harrow to Attend 2024 ASRS Annual Meeting July 12, 2024 From Harrow, Inc. Via Business Wire Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products July 09, 2024 From Harrow, Inc. Via Business Wire Harrow Provides TRIESENCE® Relaunch Update June 20, 2024 From Harrow, Inc. Via Business Wire Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery June 06, 2024 From Melt Pharmaceuticals, Inc. Via Business Wire Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study June 05, 2024 From Harrow, Inc. Via Business Wire 3 Stocks Insiders are Buying That Should be on Your Radar May 28, 2024 Unusual insider activity indicates opportunities in these stocks positioned to deliver value for shareholders this year. Via MarketBeat Harrow to Present at Two Investor Conferences in May May 15, 2024 From Harrow, Inc. Via Business Wire Harrow Announces First Quarter 2024 Financial Results May 13, 2024 From Harrow, Inc. Via Business Wire Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial May 13, 2024 From Harrow, Inc. Via Business Wire Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 April 25, 2024 From Harrow, Inc. Via Business Wire Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing April 02, 2024 From Melt Pharmaceuticals, Inc. Via Business Wire Harrow Announces Fourth Quarter and Year-End 2023 Financial Results March 19, 2024 From Harrow, Inc. Via Business Wire Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 March 05, 2024 From Harrow, Inc. Via Business Wire Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products February 15, 2024 From Harrow, Inc. Via Business Wire Harrow Announces New Appointments to its Board of Directors January 29, 2024 From Harrow, Inc. Via Business Wire Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease January 11, 2024 From Harrow, Inc. Via Business Wire Melt Pharmaceuticals Provides Corporate Update January 03, 2024 From Melt Pharmaceuticals, Inc. Via Business Wire Harrow Partners with Leading Healthcare Market Access Technology Platforms January 03, 2024 From Harrow, Inc. Via Business Wire Harrow Completes Transfer of the TRIESENCE® New Drug Application November 29, 2023 From Harrow, Inc. Via Business Wire Harrow to Present at Two Investor Conferences in November November 20, 2023 From Harrow, Inc. Via Business Wire Harrow Announces Third Quarter 2023 Financial Results November 13, 2023 From Harrow, Inc. Via Business Wire Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 October 30, 2023 From Harrow, Inc. Via Business Wire Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S. October 24, 2023 From Harrow, Inc. Via Business Wire Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. September 29, 2023 From Harrow Health, Inc. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.